216 related articles for article (PubMed ID: 29347848)
1. Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial.
Torky HA; Taha A; Marie H; El-Desouky E; Raslan O; Moussa AA; Ahmad AM; Abo-Louz A; Zaki S; Fares T; Eesa A
Climacteric; 2018 Apr; 21(2):174-178. PubMed ID: 29347848
[TBL] [Abstract][Full Text] [Related]
2. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study.
Jonasson AF; Edwall L; Uvnäs-Moberg K
Menopause Int; 2011 Dec; 17(4):120-5. PubMed ID: 22120944
[TBL] [Abstract][Full Text] [Related]
3. The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial.
Zohrabi I; Abedi P; Ansari S; Maraghi E; Shakiba Maram N; Houshmand G
BMC Womens Health; 2020 May; 20(1):108. PubMed ID: 32429977
[TBL] [Abstract][Full Text] [Related]
4. Effect of topical oxytocin gel on vaginal mucosa in postmenopausal Egyptian women: a clinical randomized trial.
Moussa A; Moberg KU; Elgrahy I; Elsayied M; Abdel-Rasheed M; Farouk M; Saad H; Meshaal H
J Sex Med; 2023 Feb; 20(2):177-183. PubMed ID: 36763919
[TBL] [Abstract][Full Text] [Related]
5. Intravaginally applied oxytocin improves post-menopausal vaginal atrophy.
Al-Saqi SH; Uvnäs-Moberg K; Jonasson AF
Post Reprod Health; 2015 Sep; 21(3):88-97. PubMed ID: 25995333
[TBL] [Abstract][Full Text] [Related]
6. Oxytocin improves cytological and histological profiles of vaginal atrophy in postmenopausal women.
Al-Saqi SH; Jonasson AF; Naessén T; Uvnäs-Moberg K
Post Reprod Health; 2016 Mar; 22(1):25-33. PubMed ID: 26883689
[TBL] [Abstract][Full Text] [Related]
7. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial.
Lima SM; Bernardo BF; Yamada SS; Reis BF; da Silva GM; Galvão MA
Maturitas; 2014 Jul; 78(3):205-11. PubMed ID: 24856055
[TBL] [Abstract][Full Text] [Related]
8. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
[No Abstract] [Full Text] [Related]
9. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial.
Fernandes T; Costa-Paiva LH; Pedro AO; Baccaro LF; Pinto-Neto AM
Menopause; 2016 Jul; 23(7):792-8. PubMed ID: 27116462
[TBL] [Abstract][Full Text] [Related]
10. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
Kingsberg SA; Derogatis L; Simon JA; Constantine GD; Graham S; Bernick B; Gasper G; Mirkin S
J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
[TBL] [Abstract][Full Text] [Related]
11. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
Simon JA; Archer DF; Kagan R; Bernick B; Graham S; Constantine GD; Mirkin S
Menopause; 2017 Sep; 24(9):1003-1010. PubMed ID: 28419068
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
13. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
Archer DF
J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.
Cruz VL; Steiner ML; Pompei LM; Strufaldi R; Fonseca FLA; Santiago LHS; Wajsfeld T; Fernandes CE
Menopause; 2018 Jan; 25(1):21-28. PubMed ID: 28763401
[TBL] [Abstract][Full Text] [Related]
15. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
[TBL] [Abstract][Full Text] [Related]
16. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of oxytocin gel in postmenopausal women with vaginal atrophy: an updated systematic review and meta-analysis.
Farahat RA; Salamah HM; Mahmoud A; Hamouda E; Hashemy M; Hamouda H; Samir A; Chenfouh I; Marey A; Awad DM; Farag E; Abd-Elgawad M; Eldesouky E
BMC Womens Health; 2023 Sep; 23(1):494. PubMed ID: 37716966
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment of vaginal atrophy with isoflavone vaginal gel.
Lima SM; Yamada SS; Reis BF; Postigo S; Galvão da Silva MA; Aoki T
Maturitas; 2013 Mar; 74(3):252-8. PubMed ID: 23312487
[TBL] [Abstract][Full Text] [Related]
19. The effect of nettle vaginal cream on subjective symptoms of vaginal atrophy in postmenopausal women.
Karimi FZ; Nazari N; Rakhshandeh H; Mazloum SR
Eur J Obstet Gynecol Reprod Biol; 2023 Jun; 285():41-45. PubMed ID: 37044017
[TBL] [Abstract][Full Text] [Related]
20. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy.
Simon JA; Maamari RV
Climacteric; 2013 Aug; 16 Suppl 1():37-43. PubMed ID: 23848490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
